公开(公告)号：US07418374B2

公开(公告)日：2008-08-26

申请号：US10207772

申请日：2002-07-31

申请人： Zvia Agur ,  Levon Arakelyan ,  Vladimir Vainstein

发明人： Zvia Agur ,  Levon Arakelyan ,  Vladimir Vainstein

IPC分类号： G06N3/00

CPC分类号： G01N33/74 ,  G01F1/3218 ,  G01F1/3263 ,  G01F1/3272 ,  G01F1/86 ,  G01N2333/515

摘要： A computer-implemented method for determining an optimal treatment protocol for a disease related to angiogenesis, comprising creating an angiogenesis model including pro-angiogenic and anti-angiogenic factors. Effective vessel density (EVD) is incorporated as a factor regulating switching on and switching off of at least one component in the angiogenesis model. Effects of vasculature maturation and mature vessel destabilization are incorporated. Pro-angiogenic and anti-angiogenic factors, which can influence changes in state of a tissue, are selected. Effects of drugs in the pro-angiogenic and anti-angiogenic factors are incorporated. A plurality of treatment protocols in a protocol space is generated. A best treatment protocol based on a pre-determined criteria is selected.

摘要翻译： 一种用于确定与血管发生相关的疾病的最佳治疗方案的计算机实现的方法，包括产生包括促血管生成和抗血管生成因子的血管生成模型。 有效血管密度（EVD）作为调节血管生成模型中至少一种成分的开启和关闭的因子而被引入。 纳入血管成熟和成熟血管不稳定的作用。 选择可影响组织状态变化的促血管生成因子和抗血管生成因子。 药物在促血管生成因子和抗血管生成因子中的作用被并入。 生成协议空间中的多个处理协议。 选择基于预定标准的最佳治疗方案。

公开(公告)号：US08489336B2

公开(公告)日：2013-07-16

申请号：US12621175

申请日：2009-11-18

申请人： Levon Arakelyan ,  Vera Selitser ,  Zvia Agur ,  Tali Eilam Tzoreff

发明人： Levon Arakelyan ,  Vera Selitser ,  Zvia Agur ,  Tali Eilam Tzoreff

IPC分类号： G06F19/00

CPC分类号： G06F19/704

摘要： A method for repurposing a pharmaceutical compound. The method includes identifying a pharmaceutical compound, the pharmaceutical compound corresponding to a drug that has failed in clinical development or an approved drug. A mathematical model describing the physiological processes related to at least one disease and the effects of the pharmaceutical compound on the disease is created. The model is adjusted based upon information from preclinical or clinical trials. A new treatment protocol is suggested to salvage the failed drug or a new way to use an approved drug. The suggested treatment protocol is displayed. Systems and computer program products encompassing the above techniques are also disclosed.

摘要翻译： 一种再利用药物化合物的方法。 该方法包括鉴定药物化合物，对应于临床开发失败的药物的药物化合物或批准的药物。 产生描述与至少一种疾病相关的生理过程和药物化合物对疾病的影响的数学模型。 该模型根据临床前或临床试验的信息进行调整。 建议采用新的治疗方案来挽救失败的药物或使用批准药物的新方法。 显示建议的治疗方案。 还公开了包括上述技术的系统和计算机程序产品。

公开(公告)号：US07970550B2

公开(公告)日：2011-06-28

申请号：US10662345

申请日：2003-09-16

申请人： Levon Arakelyan ,  Vera Selitser ,  Zvia Agur

发明人： Levon Arakelyan ,  Vera Selitser ,  Zvia Agur

IPC分类号： G06F19/00

CPC分类号： G06F19/704 ,  G06F19/00 ,  G06F19/3456 ,  G06Q50/22 ,  G16H10/20 ,  G16H50/50

摘要： A method of performing interactive clinical trials for testing a new drug. A pre-clinical phase is performed in which a computer model for pharmacokinetics and pharmacodynamics of the drug is created and adjusted based on in vitro studies and in vivo studies in animals. A phase I clinical research is performed in which a clinical trial on at least a single dose is performed in parallel with performing computer simulation studies using the computer model. An optimal protocol is determined for the most responsive patient populations and indications for a phase II clinical trial. Phase II clinical trial is performed where a number of small scale clinical trials are performed in parallel based on results of the above. Phase III clinical research is performed for chosen indications by chosen protocols. Phase IV studies are performed for post-marketing subpopulation analysis and long term product safety assessment.

摘要翻译： 执行交互式临床试验以测试新药的方法。 进行临床前阶段，其中基于动物的体外研究和体内研究，创建并调整药物的药代动力学和药效学计算机模型。 进行I期临床研究，其中使用计算机模型进行与至少一个剂量的临床试验并行执行计算机模拟研究。 确定最有反应的患者群体的最佳方案和II期临床试验的适应症。 基于上述结果，进行了多次小规模临床试验并行进行II期临床试验。 通过选择的方案对选定的指示进行III期临床研究。 进行第四阶段研究，进行营销后人群分析和长期产品安全评估。

公开(公告)号：US20080275684A1

公开(公告)日：2008-11-06

申请号：US12132300

申请日：2008-06-03

申请人： Zvia Agur ,  Levon Arakelyan ,  Vladimir Vainstein

发明人： Zvia Agur ,  Levon Arakelyan ,  Vladimir Vainstein

IPC分类号： G06G7/58

CPC分类号： G01N33/74 ,  G01F1/3218 ,  G01F1/3263 ,  G01F1/3272 ,  G01F1/86 ,  G01N2333/515

摘要： A computer-implemented method for determining an optimal treatment protocol for a disease related to angiogenesis, comprising creating an angiogenesis model including pro-angiogenesis and anti-angiogenesis factors. Effective vessel density (EVD) is incorporated as a factor regulating switching on and switching off of at least one component in the angiogenesis model. Effects of vasculature maturation and mature vessels destabilization are incorporated. Pro-angiogenesis and anti-angiogenesis factors, which can influence changes in state of a tissue are selected. Effects of drugs in the pro-angiogenesis and anti-angiogenesis factors are incorporated. A plurality of treatment protocols in a protocol space is generated. A best treatment protocol based on a pre-determined criteria.

摘要翻译： 一种用于确定与血管发生相关的疾病的最佳治疗方案的计算机实现的方法，包括产生包括促血管生成和抗血管生成因子的血管生成模型。 有效血管密度（EVD）作为调节血管生成模型中至少一种成分的开启和关闭的因子而被纳入。 引入脉管系统成熟和成熟血管不稳定的作用。 选择可影响组织状态变化的促血管发生和抗血管生成因子。 药物在促血管生成和抗血管生成因子中的作用被纳入。 生成协议空间中的多个处理协议。 基于预先确定的标准的最佳治疗方案。

公开(公告)号：US20100161301A1

公开(公告)日：2010-06-24

申请号：US12621175

申请日：2009-11-18

申请人： Levon ARAKELYAN ,  Vera Selitser ,  Zvia Agur ,  Tali Eilam Tzoreff

发明人： Levon ARAKELYAN ,  Vera Selitser ,  Zvia Agur ,  Tali Eilam Tzoreff

IPC分类号： G06G7/60

CPC分类号： G06F19/704

摘要： A method for repurposing a pharmaceutical compound. The method includes identifying a pharmaceutical compound, the pharmaceutical compound corresponding to a drug that has failed in clinical development or an approved drug. A mathematical model describing the physiological processes related to at least one disease and the effects of the pharmaceutical compound on the disease is created. The model is adjusted based upon information from preclinical or clinical trials. A new treatment protocol is suggested to salvage the failed drug or a new way to use an approved drug. The suggested treatment protocol is displayed. Systems and computer program products encompassing the above techniques are also disclosed.

摘要翻译： 一种再利用药物化合物的方法。 该方法包括鉴定药物化合物，对应于临床开发失败的药物的药物化合物或批准的药物。 产生描述与至少一种疾病相关的生理过程和药物化合物对疾病的影响的数学模型。 该模型根据临床前或临床试验的信息进行调整。 建议采用新的治疗方案来挽救失败的药物或使用批准药物的新方法。 显示建议的治疗方案。 还公开了包括上述技术的系统和计算机程序产品。